Literature DB >> 2836513

Measurement of the concentration of murine IgG monoclonal antibody in hybridoma supernatants and ascites in absolute units by sensitive and reliable enzyme-linked immunosorbent assays (ELISA).

J O Fleming1, L B Pen.   

Abstract

We have investigated an enzyme-linked immunosorbent assay (ELISA) for mouse IgG using affinity-purified goat anti-mouse antibodies for capture and detection. This assay was used to measure the absolute or weight/volume concentration of murine monoclonal antibody in hybridoma supernatants. Bovine or subclasses except IgG3 in the 1-20 ng/ml range. Antibody capture was essentially complete in the optimized assay. In combination with an antigen-dependent ELISA, the assay allowed estimation of the absolute concentration of specific monoclonal antibody in ascites. These rapid and relatively simple assays may be applicable in many situations in which a practical means of measuring murine monoclonal antibodies in weight/volume units is needed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836513      PMCID: PMC7130540          DOI: 10.1016/0022-1759(88)90077-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  22 in total

1.  Characterization of the structural proteins of the murine coronavirus strain A59 using monoclonal antibodies.

Authors:  W Gilmore; J O Fleming; S A Stohlman; L P Weiner
Journal:  Proc Soc Exp Biol Med       Date:  1987-06

2.  Quantitative measurement of human immunoglobulin E using monoclonal antibodies to distinct epitopes.

Authors:  J Sancho; F Sánchez-Madrid; O Felipe; C Bernabeu; G Morago; J Carreira
Journal:  J Immunol Methods       Date:  1986-06-10       Impact factor: 2.303

3.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

4.  The importance of antibody quality in sandwich ELISA systems. Evaluation of selected commercial reagents.

Authors:  J G Shields; M W Turner
Journal:  J Immunol Methods       Date:  1986-02-27       Impact factor: 2.303

5.  Dose-interpolation of immunoassay data: uncertainties associated with curve-fitting.

Authors:  C Kay; A B Nix; K W Kemp; R J Rowlands; G Richards; G V Groom; K Griffiths; D W Wilson
Journal:  Stat Med       Date:  1986 Mar-Apr       Impact factor: 2.373

6.  Altered recognition of surface-adsorbed compared to antigen-bound antibodies in the ELISA.

Authors:  S E Dierks; J E Butler; H B Richerson
Journal:  Mol Immunol       Date:  1986-04       Impact factor: 4.407

7.  The immunochemistry of sandwich ELISAs--I. The binding characteristics of immunoglobulins to monoclonal and polyclonal capture antibodies adsorbed on plastic and their detection by symmetrical and asymmetrical antibody-enzyme conjugates.

Authors:  J E Butler; J E Spradling; M Suter; S E Dierks; H Heyermann; J H Peterman
Journal:  Mol Immunol       Date:  1986-09       Impact factor: 4.407

8.  Measurement of monoclonal immunoglobulin concentrations in hybridoma cultures by competitive inhibition enzyme immunoassay.

Authors:  K W Hunter; J M Bosworth
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

9.  Preparation of monoclonal antibodies: strategies and procedures.

Authors:  G Galfrè; C Milstein
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

10.  An enzyme-linked double antibody immunoassay to measure murine immunoglobulins--its application to determine the specific activity of radiolabeled monoclonal antibodies.

Authors:  M R Ziai; L Imberti; S Ferrone
Journal:  J Immunol Methods       Date:  1985-10-10       Impact factor: 2.303

View more
  12 in total

1.  Weaning of three hybridoma cell lines to serum free low protein medium.

Authors:  K Radford; W Niloperbowo; S Reid; P F Greenfield
Journal:  Cytotechnology       Date:  1991-05       Impact factor: 2.058

2.  Cultivation of the hybridoma cell line MN12 in a homogeneous continuous culture system: effect of culture age.

Authors:  J M Coco-Martin; D E Martens; T A van der Velden-de Groot; E C Beuvery
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Evolution of mouse hepatitis virus: detection and characterization of spike deletion variants during persistent infection.

Authors:  C L Rowe; S C Baker; M J Nathan; J O Fleming
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Evaluation of a simple protein free medium that supports high levels of monoclonal antibody production.

Authors:  Y M Qi; P F Greenfield; S Reid
Journal:  Cytotechnology       Date:  1996-06       Impact factor: 2.058

5.  Cloning, characterization, and modeling of a monoclonal anti-human transferrin antibody that competes with the transferrin receptor.

Authors:  M Orlandini; A Santucci; A Tramontano; P Neri; S Oliviero
Journal:  Protein Sci       Date:  1994-09       Impact factor: 6.725

6.  Cytoadhesins of Mycoplasma hominis.

Authors:  B Henrich; R C Feldmann; U Hadding
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

7.  Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Authors:  Bernd Liedert; Dick Pluim; Jan Schellens; Jürgen Thomale
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

8.  Quantitation of monoclonal antibody by capture ELISA based on initial enzyme activity rate.

Authors:  Mercedes Domínguez; Inmaculada Moreno; Alfredo Toraño
Journal:  J Immunol Methods       Date:  2019-08-09       Impact factor: 2.303

9.  Monoclonal antibodies to the matrix (E1) glycoprotein of mouse hepatitis virus protect mice from encephalitis.

Authors:  J O Fleming; R A Shubin; M A Sussman; N Casteel; S A Stohlman
Journal:  Virology       Date:  1989-01       Impact factor: 3.616

10.  Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease.

Authors:  E Fazzini; J Fleming; S Fahn
Journal:  Mov Disord       Date:  1992       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.